Today's five names all just cleared earnings, and each one left behind a different open question — from a rare-disease drugmaker's FDA filing to a chip-equipment maker weighing its options.
Eton sells prescription treatments for rare pediatric conditions, and its newest launches are driving the fastest growth in the company's history. Watch for the FDA's call on an expanded Khindivi label.
View Chart →Wabtec builds the locomotives, brakes and control systems that keep freight and transit rail moving, and demand just pushed its order book to a record. The whole story now is how fast that backlog converts.
View Chart →NN makes ultra-precise metal parts for other manufacturers, and it is winning fast-growing work supplying liquid-cooling components for AI data center racks. Watch the pace of new machine installs.
View Chart →KeyCorp is the Cleveland bank behind KeyBank, and its fee engines — investment banking, payments and wealth — are outpacing the lending book. The next read is whether deal flow holds up.
View Chart →CVD Equipment builds the reactors chipmakers use to grow crystals and coatings, and it just sold a division to go all-in on that core. The catalyst now is the strategic review management has underway.
View Chart →This newsletter is for informational purposes only and does not constitute financial advice. TradersPro and its contributors are not registered investment advisors. Always conduct your own due diligence before making investment decisions. Past performance is not indicative of future results.
